Bacillus toyonensis SAU-19 Ameliorates Hepatic Insulin Resistance in High-Fat Diet/Streptozocin-Induced Diabetic Mice

Nutrients. 2021 Dec 17;13(12):4512. doi: 10.3390/nu13124512.

Abstract

Insulin resistance (IR) is a hallmark of type 2 diabetes mellitus (T2DM). This study was performed to investigate the antidiabetic effect of Bacillus toyonensis SAU-19 and its possible mechanisms of action in mice with type 2 diabetes mellitus (T2DM). Thirty SPFKM mice were randomly assigned to three groups: control, diabetic model, and diabetes + Bacillus toyonensis SAU-19 group. After 35 days, blood was collected for biochemical analysis and liver tissue samples for histopathological analysis using H&E staining, qPCR, and ELISA. The results showed that the administration of B. toyonensis SAU-19 significantly improved the blood glucose, hepatic insulin resistance, and morphological changes of the liver characterized by significant improvement of dyslipidemia, glycogen synthesis, and antioxidant status (p < 0.05), indicating the strains' ameliorating effects on hepatic insulin resistance in T2DM. In conclusion, the probiotic strain (B. toyonensis SAU-19) inhibits T2DM by reducing insulin resistance, improving antioxidant status, and downregulating genes related to glucose synthesis; hence, it may be used in treating diabetes and other metabolic disorders. This study provides the basis for further studies into the molecular mechanisms of B. toyonensis SAU-19 in treating T2DM.

Keywords: Bacillus toyonensis SAU-19; glucose synthesis; hepatic insulin resistance; type 2 diabetes.

MeSH terms

  • Animals
  • Bacillus / physiology*
  • Diabetes Mellitus, Experimental
  • Diabetes Mellitus, Type 2 / metabolism
  • Diet, High-Fat / adverse effects*
  • Insulin Resistance / physiology*
  • Liver / drug effects*
  • Liver / metabolism
  • Male
  • Mice
  • Probiotics / pharmacology*
  • Specific Pathogen-Free Organisms

Supplementary concepts

  • Bacillus toyonensis